---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058629"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:16:04.601281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024

## Summary
- Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.
- Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.
- Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.
- Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.
- Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024.

## SEC filing metadata
- accession: 0000950170-24-058629
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/0000950170-24-058629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/annx-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058629
- JSON: https://secwatch.observer/filing/0000950170-24-058629.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058629.txt

## Key facts
- Earnings Releases
  Annexon, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/0000950170-24-058629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.